BCCA Protocol Summary for Treatment of Growth Hormone Secreting Pituitary Adenoma Using Lanreotide (SOMATULINE AUTOGEL®)

Protocol Code  CNLAN

Tumour Group  Neuro-Oncology

Contact Physician  Dr. Brian Thiessen

ELIGIBILITY:
Patients with growth hormone (GH) secreting pituitary tumours
- who are not cured by surgical procedure or not a good surgical candidate and
- having persistent GH metabolic symptoms
- may be used in combination with bromocriptine (CNB), cabergoline (CNCAB) or quinagolide (CNQUIN)
- Not candidate for intramuscular injections

EXCLUSIONS:
- Pregnant or lactating women
- Complicated, untreated lithiasis of the bile ducts

TESTS:
- No specific tests apart from those required to monitor the underlying disease
- A pretreatment ultrasound of the gall bladder is recommended to rule out the formation of gallstones. Repeat ultrasound if symptoms suggestive of biliary colic while on therapy
- Blood glucose prior to therapy initiation and with dose changes
- Cardiac monitoring recommended in patients with pre-existing cardiac disorders

PREMEDICATIONS:
- None

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lanreotide (SOMATULINE AUTOGEL®)</td>
<td>60, 90 or 120 mg**</td>
<td>Deep Subcutaneous (superior outer quadrant of buttocks*) injection</td>
</tr>
</tbody>
</table>

*May use upper outer thigh for self-administration

Repeat every four weeks.

**May start with 120 mg dose if clinically indicated. Maximum dose is 120 mg every 4 weeks
DOSE MODIFICATIONS:

For patients in whom symptoms are not fully controlled within the 4 weeks, the dose of lanreotide (SOMATULINE AUTOGEL®) may be increased to a maximum of 120 mg every 4 weeks.

**Hepatic dysfunction:** Starting dose may be reduced to 60 mg

**Renal dysfunction:** Starting dose may be reduced to 60 mg

PRECAUTIONS:

- **Concomitant diabetes:** Patients on oral hypoglycemics or insulin should be monitored closely for changes in blood glucose levels for several days after the start of lanreotide (SOMATULINE AUTOGEL®) to determine the need for any dosage adjustments.

- **Previous history of gallstones.**

- **Potential for some impairment in thyroid function:** monitor for signs and symptoms of hypothyroidism.

- **Pre-existing Bradycardia** – initiate with caution and monitor heart rate

Call Dr. Brian Thiessen or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 1 Jul 2015

Date revised:

References: